Saxenda and Victoza contain exactly the same medicine, liraglutide. The difference is the dose and what each is approved for: Victoza (up to 1.8 mg a day) treats type 2 diabetes, while Saxenda (3 mg a day) is approved for weight management.
- Victoza: 0.6 mg, 1.2 mg or 1.8 mg once daily to lower blood sugar in adults and children aged 10 and older with type 2 diabetes. In adults with type 2 diabetes and heart disease, it also lowers the risk of heart attack, stroke and cardiovascular death.
- Saxenda: worked up to 3 mg once daily, with diet and exercise, for chronic weight management in adults with obesity or overweight plus a weight-related condition, and in adolescents aged 12 to 17 with obesity and a body weight over 60 kg.
- Weight loss: in its main trial, Saxenda led to about 8% average weight loss over a year, compared with about 2.6% on placebo. Victoza’s lower dose causes less weight loss.
- Never take both together: they are the same drug.
- Generics: generic liraglutide versions of both are now available in the US. Generic Victoza launched in 2024, and Teva launched the first generic Saxenda in August 2025.
- Shared warnings: a boxed warning about thyroid C-cell tumors in rodents, plus risks of pancreatitis, gallbladder problems and kidney injury from dehydration.
This is general information, not medical advice. Liraglutide is a prescription medicine. Your doctor will decide which product and dose fits your health goals and other medicines.
Saxenda vs Victoza at a glance
| Victoza | Saxenda | |
|---|---|---|
| Active ingredient | Liraglutide | Liraglutide |
| Made by | Novo Nordisk (generics available) | Novo Nordisk (generic from Teva, 2025) |
| Approved for | Type 2 diabetes (age 10+); heart risk reduction in adults with type 2 diabetes and heart disease | Chronic weight management (adults; adolescents 12 to 17 over 60 kg) |
| Maximum dose | 1.8 mg once daily | 3 mg once daily |
| Pen | Delivers 0.6, 1.2 or 1.8 mg | Delivers 0.6, 1.2, 1.8, 2.4 or 3 mg |
| Dose escalation | 0.6 mg for a week, then 1.2 mg, then 1.8 mg if needed | Increase by 0.6 mg weekly over 5 weeks to 3 mg |
| Average weight loss in trials | About 2 to 3 kg | About 8% of body weight at 56 weeks |
| Boxed warning | Thyroid C-cell tumors | Thyroid C-cell tumors |
| Usually covered by insurance for | Type 2 diabetes | Weight loss coverage varies widely |
What is liraglutide?
Liraglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone your gut releases after eating. It:
- prompts the pancreas to release insulin when blood sugar is high
- lowers glucagon, a hormone that raises blood sugar
- slows emptying of the stomach, so you feel full longer
- acts on appetite centers in the brain to reduce hunger
Liraglutide was the first once-daily GLP-1 drug to become widely used. It has since been overtaken by once-weekly drugs such as semaglutide (Ozempic, Wegovy) and dual-action tirzepatide (Mounjaro, Zepbound), which produce more weight loss. Liraglutide remains important because it now has cheaper generic versions and a long safety track record.
Why the same drug has two brand names
Novo Nordisk first developed liraglutide for diabetes as Victoza, approved in 2010. Trials then showed that a higher dose (3 mg) produced meaningful weight loss in people without diabetes, so the company sought a separate approval for weight management. Saxenda was approved for that in December 2014.
Different doses, indications, trial programs and pricing led to two separate products. That’s a common pattern: semaglutide is sold as Ozempic for diabetes and Wegovy for weight, and tirzepatide as Mounjaro and Zepbound.
Dosing compared
Victoza
- Start with 0.6 mg once daily for 1 week. This starting dose reduces stomach side effects; it does not control blood sugar well.
- Increase to 1.2 mg once daily.
- If more blood sugar control is needed, increase to 1.8 mg after at least another week.
Saxenda
| Week | Daily dose |
|---|---|
| 1 | 0.6 mg |
| 2 | 1.2 mg |
| 3 | 1.8 mg |
| 4 | 2.4 mg |
| 5 and onward | 3 mg (maintenance) |
Adolescents follow a similar schedule; if they cannot tolerate 3 mg, they may stay on 2.4 mg. The label tells adults to stop Saxenda if they have not lost at least 4% of their body weight after 16 weeks at the maintenance dose, because they are unlikely to achieve meaningful weight loss with continued treatment.
Both are injected under the skin of the stomach, thigh or upper arm, once a day at any time, with or without food. If you miss 3 or more days, the dose should be restarted at 0.6 mg and stepped up again to limit nausea.
How well do they work?
Victoza for type 2 diabetes
In the LEAD trials, liraglutide lowered HbA1c by roughly 1 to 1.5 percentage points depending on the starting level and other medicines. In the LEADER trial (9,340 adults with type 2 diabetes and high cardiovascular risk), liraglutide 1.8 mg reduced major cardiovascular events (cardiovascular death, heart attack or stroke) from 14.9% to 13.0%, a 13% relative reduction, and lowered cardiovascular death. That is why Victoza carries a heart-protection indication.
Saxenda for weight management
The SCALE trials tested liraglutide 3 mg in more than 5,000 people:
- SCALE Obesity and Prediabetes: about 8% average weight loss at 56 weeks with liraglutide vs about 2.6% with placebo. About 63% of people lost at least 5% of their weight, compared with 27% on placebo.
- SCALE Diabetes: in people with type 2 diabetes, weight loss was smaller (about 6% vs 2%), which is typical for all weight-loss drugs.
- SCALE Maintenance: after losing at least 5% through diet, 81% of people on liraglutide kept the weight off over a year, compared with 49% on placebo.
For comparison, semaglutide 2.4 mg (Wegovy) produces about 15% average weight loss and tirzepatide (Zepbound) about 20% in their main trials. So Saxenda is now a lower-efficacy option, though its generic availability can make it much more affordable.
Side effects
Because they contain the same drug, Saxenda and Victoza share the same side effects. They are usually more frequent with Saxenda’s higher dose.
Common side effects
- nausea (the most common; often fades after the first few weeks)
- diarrhea, constipation and vomiting
- reduced appetite, indigestion and stomach pain
- headache and tiredness
- injection-site reactions
- low blood sugar, mainly when combined with insulin or sulfonylureas
Serious risks
- Thyroid C-cell tumors (boxed warning): liraglutide caused these tumors in rats and mice. It is unknown whether it does in humans. Do not use liraglutide if you or a family member has had medullary thyroid carcinoma or if you have multiple endocrine neoplasia type 2 (MEN 2).
- Pancreatitis: stop the medicine and seek care for severe stomach pain that may spread to the back, with or without vomiting.
- Gallbladder disease: gallstones and gallbladder inflammation are more common, partly due to rapid weight loss.
- Kidney injury: from dehydration caused by vomiting or diarrhea. Drink fluids and contact your doctor if you can’t keep them down.
- Severe stomach and bowel problems: the 2025 labels strengthened warnings about severe gastrointestinal reactions.
- Fast heart rate: liraglutide raises resting heart rate by a few beats per minute.
- Pulmonary aspiration during anesthesia: because the stomach empties slowly, tell your anesthetist you take it before any procedure with sedation.
- Allergic reactions: rare but possible.
Label updates worth knowing
- 2025: the Saxenda label removed pregnancy from its contraindications. Weight loss offers no benefit during pregnancy, so talk to your doctor about stopping it if you become pregnant or are planning a pregnancy.
- 2026: the FDA removed the specific warning about suicidal behavior and ideation from Saxenda’s label after reviewing the evidence. Anyone with new or worsening depression or suicidal thoughts should still seek help immediately.
Can you switch from Victoza to Saxenda?
Yes, under your doctor’s direction, since it’s the same drug. Someone with type 2 diabetes on Victoza 1.8 mg who wants more weight loss could be moved to Saxenda and stepped up to 2.4 mg and then 3 mg. Never take both at once. In practice, many doctors now choose a once-weekly drug instead, such as semaglutide or tirzepatide, which give more weight loss and better blood sugar control.
If you take insulin, note that Saxenda has not been studied with insulin, and the label advises against using them together. Victoza can be used with insulin under careful monitoring.
Cost and availability
- Generic liraglutide (Victoza equivalent) has been available in the US since 2024 and is often much cheaper than the brand.
- Generic liraglutide (Saxenda equivalent) became available when Teva launched the first generic in August 2025. It was the first generic GLP-1 approved for weight loss.
- Insurance: most plans cover liraglutide for type 2 diabetes. Coverage for weight management varies widely, and Medicare generally excludes drugs used for weight loss alone.
Pens of Victoza and generic liraglutide for diabetes are not intended to deliver the 2.4 mg and 3 mg doses used for weight management. Use the product your prescriber specifies.
Who might choose which?
| Your situation | Typical choice |
|---|---|
| Type 2 diabetes, especially with heart disease | Victoza or generic liraglutide (or a once-weekly GLP-1) |
| Obesity without diabetes, cost a priority | Generic Saxenda (liraglutide 3 mg) |
| Obesity, maximum weight loss wanted | Wegovy or Zepbound, which typically lead to more weight loss |
| Teenager aged 12 to 17 with obesity | Saxenda or Wegovy, both approved for adolescents |
| Child aged 10 to 17 with type 2 diabetes | Victoza |
| History of medullary thyroid cancer or MEN 2 | Neither |
Frequently asked questions
What is the difference between Saxenda and Victoza?
They contain the same drug, liraglutide. Victoza is approved for type 2 diabetes at up to 1.8 mg a day, and also lowers heart risk in adults with diabetes and heart disease. Saxenda is approved for weight management at 3 mg a day.
Is Saxenda stronger than Victoza?
Saxenda’s maintenance dose (3 mg) is higher than Victoza’s maximum (1.8 mg), so it causes more weight loss and usually more nausea. It’s the same medicine at a higher dose.
Can I use Victoza for weight loss?
Victoza is not FDA-approved for weight loss, although it often causes a few kilograms of weight loss in people with diabetes. Saxenda is the liraglutide product approved for weight management.
How much weight can you lose on Saxenda?
In the main trial, people lost about 8% of their body weight on average over a year, compared with about 2.6% on placebo. Results vary, and the label advises stopping if you haven’t lost 4% after 16 weeks on the full dose.
Is there a generic Saxenda?
Yes. Teva launched the first generic Saxenda (liraglutide injection) in the US in August 2025. Generic versions of Victoza have been available since 2024.
Can you take Saxenda and Victoza together?
No. They contain the same active ingredient, so taking both would double the dose of liraglutide and raise the risk of side effects.
Is liraglutide as effective as Ozempic or Wegovy?
No. Semaglutide (Ozempic, Wegovy) generally lowers blood sugar more and produces more weight loss, and is taken once a week rather than daily. Liraglutide’s advantages are a long track record and cheaper generic versions.
References
- FDA. SAXENDA (liraglutide) prescribing information, revised 2026
- FDA. VICTOZA (liraglutide) prescribing information
- Teva. Teva announces FDA approval and launch of generic Saxenda, August 2025
- Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE). N Engl J Med. 2015;373:11-22
- Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375:311-322
- European Medicines Agency. Saxenda product information
Try our interactive tool: GLP-1 weight loss drug comparison tool
Compare Zepbound, Wegovy, the Wegovy pill, Foundayo and Saxenda side by side.
About this article
Written by the Health Linear Editorial Team from primary sources such as FDA prescribing information, DailyMed, NIH and peer-reviewed studies, which are linked in the article. Last updated October 30, 2026.
Read our editorial process and medical disclaimer. Spotted an error? Tell us and we will correct it.